calpastatin and Diabetes-Mellitus--Type-2

calpastatin has been researched along with Diabetes-Mellitus--Type-2* in 2 studies

Reviews

1 review(s) available for calpastatin and Diabetes-Mellitus--Type-2

ArticleYear
Calpains and human disease.
    Sub-cellular biochemistry, 2007, Volume: 45

    Calpains, particularly conventional dimeric calpains, have claimed to be involved in the cell degeneration processes that characterize numerous disease conditions linked to dysfunctions of cellular Ca2+ homeostasis. The evidence supporting their involvement has traditionally been indirect and circumstantial, but recent work has added more solid evidence supporting the role of ubiquitous dimeric calpains in the process of neurodegeneration. The only disease condition in which a calpain defect has been conclusively involved concerns an atypical monomeric calpain: the muscle specific calpain-3, also known as p94. Inactivating defects in its gene cause a muscular dystrophy termed LGMD-2A. The molecular mechanism by which the absence of the proteolytic activity of calpain-3 causes the dystrophic process is unknown. Another atypical calpain, which has been characterized recently as a Ca2(+)-dependent protease, calpain 10, appears To be involved in the etiology of type 2 diabetes. The involvement has been inferred essentially from genetic evidence. Also in the case of type 2 diabetes the molecular mechanisms that could link the disease to calpain 10 are unknown.

    Topics: Animals; Calcium; Calcium-Binding Proteins; Calpain; Connectin; Diabetes Mellitus, Type 2; Humans; Muscle Proteins; Muscular Dystrophies, Limb-Girdle; Neurodegenerative Diseases; Protein Kinases

2007

Other Studies

1 other study(ies) available for calpastatin and Diabetes-Mellitus--Type-2

ArticleYear
    JCI insight, 2016, 11-03, Volume: 1, Issue:18

    The islet in type 2 diabetes (T2D) shares many features of the brain in protein misfolding diseases. There is a deficit of β cells with islet amyloid derived from islet amyloid polypeptide (IAPP), a protein coexpressed with insulin. Small intracellular membrane-permeant oligomers, the most toxic form of IAPP, are more frequent in β cells of patients with T2D and rodents expressing human IAPP. β Cells in T2D, and affected cells in neurodegenerative diseases, share a comparable pattern of molecular pathology, including endoplasmic reticulum stress, mitochondrial dysfunction, attenuation of autophagy, and calpain hyperactivation. While this adverse functional cascade in response to toxic oligomers is well described, the sequence of events and how best to intervene is unknown. We hypothesized that calpain hyperactivation is a proximal event and tested this in vivo by β cell-specific suppression of calpain hyperactivation with calpastatin overexpression in human IAPP transgenic mice. β Cell-specific calpastatin overexpression was remarkably protective against β cell dysfunction and loss and diabetes onset. The critical autophagy/lysosomal pathway for β cell viability was protected with calpain suppression, consistent with findings in models of neurodegenerative diseases. We conclude that suppression of calpain hyperactivation is a potentially beneficial disease-modifying strategy for protein misfolding diseases, including T2D.

    Topics: Animals; Calcium-Binding Proteins; Calpain; Diabetes Mellitus, Type 2; Female; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Mice; Mice, Transgenic

2016